ReviewJournal of Cancer2018
Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.
Review in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2020Pooled it
- Multimodal analysis of cell-free DNA enhances differentiation of early-stage breast cancer from benign lesions and healthy individuals.BMC biology · 2025Article
- Liquid biopsy in triple-negative breast cancer: a promising tool for diagnosis, prognosis, and treatment monitoring.Frontiers in oncology · 2025Review
- Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies.International journal of molecular sciences · 2024Article
- Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.BMC cancer · 2024Article
- Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice.Medicina (Kaunas, Lithuania) · 2024Review
- Substrate stiffness modulates extracellular vesicles' release in a triple-negative breast cancer model.Extracellular vesicles and circulating nucleic acids · 2024Article
- Roles of long noncoding RNA in triple-negative breast cancer.Cancer medicine · 2023Review
- Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer.MedComm · 2022Article
- Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer.Cancers · 2022Article
- Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review.Breast cancer (Dove Medical Press) · 2022Review
- Circulating tumor DNA - A potential aid in the management of chordomas.Frontiers in oncology · 2022Review
- Comparison of PICC and TIVAP in chemotherapy for patients with thyroid cancer.Oncology letters · 2020Article
- Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer.Diagnostics (Basel, Switzerland) · 2020Article
- Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.International journal of molecular sciences · 2020Review
- Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.NPJ breast cancer · 2020Review
- Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology.Frontiers in oncology · 2020Review
- Potential value of circulating tumor DNA in gynecological tumors.American journal of translational research · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a specific subtype of breast cancer, Triple-negative breast cancer (TNBC) is associated with worse prognosis and higher tumor aggressiveness than HER2-amplified or hormone receptor positive breast cancers. Circulating tumor DNA (ctDNA), as a non-invasive "liquid biopsy", is an emerging original blood-based biomarker for early breast cancer diagnosis, monitoring treatment response, and determining prognosis. In TNBC patients, ctDNA has an inherent tendency to characterize tumor heterogeneity and metastasis-specific mutations providing a key alternative to tumor tissue profiling. Several studies have already demonstrated the potential of ctDNA in TNBC patients from early to advanced stages of the disease including diagnosis, therapy decisions and assessment of prognosis. This review provides a critical brief summary of the evidence that gives credence to the utility of ctDNA as a biomarker for its role into clinical management in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.